TY - JOUR
T1 - Patiënten met type 2-diabetes en een laag cardiovasculair risico
T2 - Welke glucoseverlager volgt na metformine?
AU - Serne, Erik H.
AU - Sikkens, Jonne J.
AU - Ijzerman, Richard G.
PY - 2023
Y1 - 2023
N2 - In persons with type 2 diabetes without established cardiovascular complications data are lacking on the comparative effectiveness of commonly used glucose-lowering medications, when added to metformin, with respect to glycemic outcomes as well as microvascular and cardiovascular disease outcomes. The GRADE trial compared the ability of four glucose-lowering remedies to achieve and maintain a defined glycated hemoglobin target and to protect the participant from microvascular and macrovascular complications. In this article, we comment on the relevance of this trial with specific attention for the notion that GLP-1 receptor agonists seem to have a primary preventive effect.
AB - In persons with type 2 diabetes without established cardiovascular complications data are lacking on the comparative effectiveness of commonly used glucose-lowering medications, when added to metformin, with respect to glycemic outcomes as well as microvascular and cardiovascular disease outcomes. The GRADE trial compared the ability of four glucose-lowering remedies to achieve and maintain a defined glycated hemoglobin target and to protect the participant from microvascular and macrovascular complications. In this article, we comment on the relevance of this trial with specific attention for the notion that GLP-1 receptor agonists seem to have a primary preventive effect.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85193747175&origin=inward
M3 - Article
SN - 0028-2162
VL - 167
JO - Nederlands tijdschrift voor geneeskunde
JF - Nederlands tijdschrift voor geneeskunde
IS - 44
M1 - D7568
ER -